Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Industry Network.
Press releases published on August 14, 2025
SafeHeal® Receives European Marketing Approval Under MDR for Colovac® Anastomosis Protection Technology
EIN Presswire
·
August 14, 2025
Marketing approval allows imminent commercialization of the Colovac device in key EU markets NEW YORK, NY, UNITED STATES, August 14, 2025 /EINPresswire.com/ -- SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced …
Global Polyisoprene Rubber Market Size to Reach $3.64 Billion by 2034, Growing at 4% CAGR
EIN Presswire
·
August 14, 2025
The global polyisoprene rubber market size was worth around USD 2.66 billion in 2024 and is predicted to grow to around USD 3.64 billion by 2034 PUNE, MAHARASHTRA, INDIA, August 14, 2025 /EINPresswire.com/ -- 📊 Global Polyisoprene Rubber Market Research …
Groupe IT Link : +0,8% de croissance du chiffre d’affaires au S1 2025
GlobeNewswire
·
August 14, 2025
Communiqué Financier Le Kremlin-Bicêtre, le 14 août 2025 Un premier semestre résilient malgré un marché attentiste Répartition par pays En M€ S1 2024 (1) S1 2025 (1) Variation France 35,30 35,07 -0,7% International 6,64 7,22 +8,7% Chiffre d’affaires 41, …
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
GlobeNewswire
·
August 14, 2025
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores …
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4
GlobeNewswire
·
August 14, 2025
Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025 …